The transcript discusses the use of technology to improve patient health, focusing on diabetes management and other innovative projects. It highlights partnerships with companies like Dexcom and Sanofi, and the balance between health missions and revenue. The company benefits from being a subsidiary of Alphabet, allowing for significant investment and collaboration with academic institutions. Key lessons from biotech startups emphasize scientific rigor, team building, and transparency.

What are some ways technologies can improve the lives of patients with diabetes?

How does the partnership with Dexcom contribute to diabetes treatment?

In what ways does the company aim to shift the needle on health and disease?

What is the significance of scientific rigor in health technology development?

What are the three key messages for managing public expectations in biotech?